🇺🇸 FDA

Intelligence · Clinical Pipeline

CORCEPT THERAPEUTICS Pipeline

All ClinicalTrials.gov programs at CORCEPT THERAPEUTICS — phase, modality, and trial IDs.

Programs
67

Quick answer

CORCEPT THERAPEUTICS has 67 clinical development programs indexed from ClinicalTrials.gov, including phase, modality, indication text, and linked NCT identifiers.

  1. An Open-Label Extension Study of the Safety of Relacorilant (CORT125134) in the Treatment of the Signs and Symptoms of Endogenous Cushing Syndrome

    CORCEPT THERAPEUTICS INC

    Endogenous Cushing Syndrome

    phase 3 other active

    1 trial

  2. Mifepristone

    CORCEPT THERAPEUTICS INC

    Depressive Disorder, Major

    phase 3 small molecule completed

    1 trial

  3. Nab-paclitaxel 80 mg/m^2

    CORCEPT THERAPEUTICS INC

    Ovarian Neoplasm

    phase 3 small molecule active

    1 trial

  4. Relacorilant

    CORCEPT THERAPEUTICS INC

    Hypercortisolism

    phase 3 small molecule completed

    1 trial

  5. Relacorilant, 100 mg and 25 mg

    CORCEPT THERAPEUTICS INC

    Metastatic Pancreatic Ductal Adenocarcinoma

    phase 3 small molecule terminated

    1 trial

  6. mifepristone

    CORCEPT THERAPEUTICS INC

    Major Depressive Disorder

    phase 3 small molecule completed

    5 trials

  7. mifepristone

    CORCEPT THERAPEUTICS INC

    Cushing's Syndrome

    phase 3 small molecule completed

    2 trials

  8. mifepristone

    CORCEPT THERAPEUTICS INC

    Cushing's Disease

    phase 3 small molecule terminated

    2 trials

  9. mifepristone

    CORCEPT THERAPEUTICS INC

    Psychotic Depression

    phase 3 small molecule terminated

    1 trial

  10. relacorilant

    CORCEPT THERAPEUTICS INC

    Cushing Syndrome

    phase 3 small molecule active

    2 trials

  11. relacorilant, CORT125134, Abraxane 5 mg/ml powder for dispersion for infusion.

    CORCEPT THERAPEUTICS INC

    Advanced, Platinum-Resistant, High-Grade Epithelial Ovarian, Primary Peritoneal, or Fallopian-Tube Cancer

    phase 3 small molecule active

    1 trial

  12. CORT113176, CORT113176, Placebo to Dazucorilant softgel capsule

    CORCEPT THERAPEUTICS INC

    Amyotrophic Lateral Sclerosis

    phase 2 small molecule active

    1 trial

  13. CORT125134

    CORCEPT THERAPEUTICS INC

    Cushing's Syndrome

    phase 2 small molecule completed

    1 trial

  14. CORT125134, PACLITAXEL ALBUMIN-BOUND, BEVACIZUMAB, relacorilant

    CORCEPT THERAPEUTICS INC

    Gynecological Cancers

    phase 2 small molecule active

    1 trial

  15. Dazucorilant 300 mg

    CORCEPT THERAPEUTICS INC

    Amyotrophic Lateral Sclerosis

    phase 2 small molecule active

    1 trial

  16. Enzalutamide

    CORCEPT THERAPEUTICS INC

    Metastatic Breast Cancer

    phase 2 small molecule active

    1 trial

  17. Exicorilant

    CORCEPT THERAPEUTICS INC

    Metastatic Castration-Resistant Prostate Cancer

    phase 2 small molecule terminated

    1 trial

  18. Mifepristone

    CORCEPT THERAPEUTICS INC

    Non-Small Cell Lung Cancer (NSCLC)

    phase 2 small molecule terminated

    1 trial

  19. Mifepristone

    CORCEPT THERAPEUTICS INC

    Weight-Gain Prevention

    phase 2 small molecule completed

    1 trial

  20. Mifepristone

    CORCEPT THERAPEUTICS INC

    Central Adrenal Insufficiency

    phase 2 small molecule terminated

    1 trial

  21. Mifepristone

    CORCEPT THERAPEUTICS INC

    Alzheimer's Disease

    phase 2 small molecule terminated

    1 trial

  22. Mifepristone 1200 mg daily

    CORCEPT THERAPEUTICS INC

    Treatment-resistant PTSD

    phase 2 small molecule active

    1 trial

  23. Miricorilant

    CORCEPT THERAPEUTICS INC

    Antipsychotic-induced Weight Gain (AIWG)

    phase 2 small molecule completed

    1 trial

  24. Miricorilant

    CORCEPT THERAPEUTICS INC

    Nonalcoholic Steatohepatitis (NASH)

    phase 2 small molecule active

    3 trials

  25. Miricorilant (Cohort A)

    CORCEPT THERAPEUTICS INC

    Nonalcoholic Steatohepatitis (NASH)

    phase 2 small molecule active

    1 trial

  26. Miricorlilant

    CORCEPT THERAPEUTICS INC

    Antipsychotic-induced Weight Gain (AIWG)

    phase 2 small molecule completed

    1 trial

  27. Nenocorilant 200 mg

    CORCEPT THERAPEUTICS INC

    Neoplasms

    phase 2 small molecule active

    1 trial

  28. Relacorilant

    CORCEPT THERAPEUTICS INC

    Recurrent Ovarian Cancer

    phase 2 small molecule completed

    1 trial

  29. Relacorilant 150 mg once daily (QD)

    CORCEPT THERAPEUTICS INC

    Ovarian Cancer

    phase 2 small molecule active

    1 trial

  30. Relacorilant 150 mg once daily (QD)

    CORCEPT THERAPEUTICS INC

    Adenocarcinoma

    phase 2 small molecule active

    1 trial

  31. Relacorilant with nab-paclitaxel

    CORCEPT THERAPEUTICS INC

    Solid Tumors

    phase 2 small molecule completed

    1 trial

  32. 14C-CORT125281

    CORCEPT THERAPEUTICS INC

    Healthy

    phase 1 small molecule completed

    1 trial

  33. CORT113176

    CORCEPT THERAPEUTICS INC

    Healthy Adults

    phase 1 small molecule completed

    1 trial

  34. CORT113176 Lipid Capsule Formulation

    CORCEPT THERAPEUTICS INC

    Healthy Adults

    phase 1 small molecule completed

    1 trial

  35. CORT118335 Oral

    CORCEPT THERAPEUTICS INC

    Healthy

    phase 1 small molecule completed

    1 trial

  36. CORT118335, 25 mg

    CORCEPT THERAPEUTICS INC

    Healthy

    phase 1 small molecule completed

    1 trial

  37. CORT125134

    CORCEPT THERAPEUTICS INC

    Healthy

    phase 1 small molecule completed

    2 trials

  38. CORT125134 150 mg

    CORCEPT THERAPEUTICS INC

    Healthy

    phase 1 small molecule completed

    1 trial

  39. CORT125236

    CORCEPT THERAPEUTICS INC

    Healthy

    phase 1 small molecule completed

    1 trial

  40. CORT125281, 40mg, fasted

    CORCEPT THERAPEUTICS INC

    Healthy

    phase 1 small molecule completed

    1 trial

  41. CORT125329 lipid capsule formulation

    CORCEPT THERAPEUTICS INC

    Healthy

    phase 1 small molecule completed

    1 trial

  42. Dabigatran Etexilate

    CORCEPT THERAPEUTICS INC

    Cushing Syndrome

    phase 1 small molecule completed

    1 trial

  43. Dazucorilant

    CORCEPT THERAPEUTICS INC

    Hepatic Impairment

    phase 1 small molecule completed

    1 trial

  44. Dazucorilant

    CORCEPT THERAPEUTICS INC

    Healthy Adults

    phase 1 small molecule completed

    1 trial

  45. Enzalutamide

    CORCEPT THERAPEUTICS INC

    Prostate Cancer

    phase 1 small molecule completed

    1 trial

  46. Midazolam hydrochloride

    CORCEPT THERAPEUTICS INC

    Healthy

    phase 1 small molecule completed

    1 trial

  47. Mifepristone

    CORCEPT THERAPEUTICS INC

    Healthy

    phase 1 small molecule completed

    1 trial

  48. Mifepristone 300 MG

    CORCEPT THERAPEUTICS INC

    Drug Interaction Potentiation

    phase 1 small molecule completed

    1 trial

Frequently asked questions

How many pipeline programs does CORCEPT THERAPEUTICS have?

67 published programs are linked to this sponsor in our ClinicalTrials.gov index.

Is this the complete company pipeline?

This hub lists all published programs for the sponsor in our database. Partnered or out-licensed assets may appear under multiple companies.

Data attribution: Data sources · All pipeline programs

Drug approvals, clinical trials, M&A, event intelligence, and company updates — weekly.

Customize topics & region
Topics
Region

No spam. Unsubscribe anytime. See our privacy policy.